| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Pharmaceuticals (Health Care sector), BCRX's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 1.34M | $13.00M | - | |
| CFO | 268.7K | - | - | |
| Other | 205.2K | - | - | |
| Dir | 109.6K | $1.06M | - | |
| Dir | 80.6K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 19, 2016 | Staab Thomas R II | Senior Vice President And CFO | Sale+OE | 3,250 | $7.45 | $24,212.50 | -2.6% | |
| Sep 14, 2016 | Barnes Alane P70 | VP, General Counsel &Corp Sec | Sell | 8,357 | $4.27 | $35,684.39 | -9.5% | |
| Aug 25, 2016 | Babu Yarlagadda S66 | Senior VP - Drug Discovery | Sell | 30,000 | $4.06 | $121,800.00 | -21.2% | |
| Aug 16, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Sell | 4,046,590 | $5.00 | $20,251,102.77 | -30.1% | |
| Aug 12, 2016 | Staab Thomas R II | Senior Vice President And CFO | Sell | 5,864 | $5.18 | $30,388.06 | -4.5% | |
| Aug 9, 2016 | Staab Thomas R II | Senior Vice President And CFO | Sell | 14,577 | $4.43 | $64,576.11 | -10.1% | |
| Feb 5, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 45,000 | $6.33 | $284,656.50 | +0.4% | |
| Feb 4, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 207,715 | $6.43 | $1,336,586.04 | +1.6% | |
| Jan 28, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 88,345 | $6.95 | $613,985.73 | +0.7% | |
| Jan 22, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 106,800 | $7.28 | $777,757.44 | +0.9% |